Hill’s “Biological Plausibility” Criterion: Integration of Data from Various Disciplines for Epidemiology and Radiation Epidemiology

2021 ◽  
Vol 48 (11) ◽  
pp. 1991-2014
Author(s):  
A. N. Koterov ◽  
L. N. Ushenkova ◽  
A. P. Biryukov
Author(s):  
Margit L. Bleecker

This chapter describes neurologic disorders related primarily to occupational exposures along with presenting signs and symptoms. Acute or subacute occupational exposure to high levels of neurotoxic compounds, which occurred in the past and resulted in unique presentations of neurological disorders, occur infrequently today. Sections include the evaluation of toxic neuropathies and the approach to neurobehavioral impairment along with the cognitive domains commonly affected with exposure to neurointoxicants. A section describes the approach to a patient with exposure to neurointoxicants that includes the need for a temporal association between exposure and effect, a dose-effect relationship, biological plausibility, and other causes eliminated Effects of selected neurotoxins are described, including carbon monoxide, lead, organic solvents, and manganese.


Author(s):  
Donald L. Bliwise ◽  
Michael K. Scullin

Possible associations between sleep and cognition are provocative across different domains and hold the promise of prevention or reversibility. A vast array of studies has been reported. Evidence is suggestive but hardly definitive. We provide an overview of this literature, adopting the framework of Hill’s perspective on epidemiological causation. With rare exception, formal meta-analyses have yet to appear. Apparent consistency of findings suggests relationships, but the diversity of findings involving specific components of cognitive function raises interpretative caution. Large effect sizes have been noted, but small-to-moderate effects predominate. Natural history data are similarly enticing, and studies of biological plausibility and gradient indicate likely neurobiological substrates. Perhaps the ultimate population-health criterion, demonstration of reversibility of impairment, remains elusive at best. This area offers an exciting topic for future work.


2007 ◽  
Vol 17 (S2) ◽  
pp. S97-S105 ◽  
Author(s):  
James S Brown ◽  
Judith A Graham ◽  
Lung Chi Chen ◽  
Edward M Postlethwait ◽  
Andrew J Ghio ◽  
...  

2005 ◽  
Vol 11 (3) ◽  
Author(s):  
Rashmi R Shah

The implementation of Community Regulation on orphan medicinal products in the European Union in April 2000 has resulted in a deluge of applications for designation of medicinal products as orphan for rare diseases. By April 2004, the Committee for Orphan Medicinal Products had already given positive opinion on 63 per cent of the 316 applications considered by them. A significant number of these positive designations have already matured into full marketing authorisations. Three major reasons – failure to meet prevalence or significant benefit criteria or provide evidence of biological plausibility – have equally contributed to either the negative opinion on or the applicants withdrawing the remaining applications. In July 2004, the European Commission issued a communication setting out its position on certain matters relating to the implementation of the designation and market exclusivity provisions. The Commission, the European Medicines Agency (EMEA) and the Committee for Orphan Medicinal Products (COMP) continue to be proactive and provide as much guidance and incentives as practical, engaging themselves with sponsors, patient groups and academia. As experience builds up and issues are clarified, there are expectations that the Community Regulation on orphan medicines will prove to be a spectacular success.


2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Elisabetta Bigagli ◽  
Lorenzo Cinci ◽  
Mario D’Ambrosio ◽  
Patrizia Nardini ◽  
Francesca Portelli ◽  
...  

Recent studies reported the association between increased risk of nonmelanoma skin cancers (NMSCs) and the use of hydrochlorothiazide (HCTZ), one of the most commonly prescribed diuretic, antihypertensive drug, over the world. Although HCTZ is known to be photosensitizing, the mechanisms involved in its potential prophotocarcinogenic effects remain unclear. Under acute exposure, therapeutically relevant concentrations of HCTZ (70, 140, and 370 ng/mL) amplified UVA-induced double-strand breaks, oxidative DNA, and protein damage in HaCaT human keratinocytes, and this effect was associated to a defective activity of the DNA repair enzyme, OGG1. Oxidative damage to DNA, but not that to proteins, was reversible within few hours. After chronic, combined exposure to HCTZ (70 ng/mL) and UVA (10 J/cm2), for 9 weeks, keratinocytes acquired a dysplastic-like phenotype characterized by a multilayered morphology and alterations in cell size, shape, and contacts. At the ultrastructural level, several atypical and enlarged nuclei and evident nucleoli were also observed. These transformed keratinocytes were apoptosis resistant, exhibited enhanced clonogenicity capacity, increased DNA damage and inflammation, defective DNA repair ability, and increased expression of the oncogene ΔNp63α and intranuclear β-catenin accumulation (a hallmark of Wnt pathway activation), compared to those treated with UVA alone. None of these molecular, morphological, or functional effects were observed in cells treated with HCTZ alone. All these features resemble in part those of preneoplastic lesions and NMSCs and provide evidence of a biological plausibility for the association among exposure to UVA, use of HCTZ, and increased risk of NMSCs. These results are of translational relevance since we used environmentally relevant UVA doses and tested HCTZ at concentrations that reflect the plasma levels of doses used in clinical practice. This study also highlights that drug safety data should be followed by experimental evaluations to clarify the mechanistic aspects of adverse events.


Sign in / Sign up

Export Citation Format

Share Document